Next Generation Point of Care Platform
SpinChip Diagnostics is developing a game changing and proprietary platform for in vitro diagnostics point of care analyses. The platform will make it possible to perform a broader range of analyses using one platform and to transfer analyses from central laboratories to point of care without loss in quality. All analyses are performed within a few minutes based on a fraction of a droplet of blood and at a unit cost significantly lower than other point of care platforms.
The SpinChip Technology
The SpinChip platform represents a quantum leap within advanced and ultrafast multianalyte point of care in vitro diagnostics. This is obtained by combining patented, game changing technologies within lab-on-a-chip microfluidics and assaying with unique ultrasensitive chemistries and two proprietary readout technologies.
The flexibility and efficiency of the combined technologies makes the SpinChip platform truly versatile both in sample processing, assaying and measurements. The platform will be applied to multiple clinical fields utilising the optimal fluidics and readout required. SpinChip has presently two assaying concepts in pipeline respectively for high sensitivity cardiac Troponin I and CRP. SpinChip will further utilise the unique technology within multiple application areas in collaboration with selected competent partners.
The SpinChip team has a proven track record with the competence required to successfully develop and commercialize the SpinChip platform. We have top level personnel within all key technology fields of the platform and believe in building a cutting edge, cross-disciplinary team. By early 2017 we are close to 20 highly qualified individuals, all passionate about creating a game changing point of care platform.